Press releaseGlobe Newswire
Entera Bio
ENTX · NASDAQ
$3.02+$0.08 (+2.72%)TodayMarket closed ·
Prev close $2.94
Latest news
- NewsAvi Kapoor
Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Press releaseGlobe Newswire
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
- Press releaseGlobe Newswire
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
- NewsAvi Kapoor
Oxford Industries Posts Mixed Q2 Results, Joins Asana, Lululemon Athletica And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Press releaseGlobe Newswire
Correction: Entera to Participate in Upcoming Fall Investor Conferences
- Press releaseGlobe Newswire
Entera to Participate in Upcoming Fall Investor Conferences
- Press releaseGlobe Newswire
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
- Press releaseGlobe Newswire
Entera Announces Second Quarter 2026 Financial Results and Business Updates
- Press releaseGlobe Newswire
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
- Press releaseGlobe Newswire
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
- Press releasePRNewswire
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
- NewsAkanksha Bakshi
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
- NewsAvi Kapoor
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June
- NewsAvi Kapoor
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
- Press releaseGlobe Newswire
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
Entera Bio Announces FDA Has Provided Positive Feedback On The Phase 3 Protocol For EB613, The Company's Oral Osteoporosis Tablet
- Press releaseGlobe Newswire
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
- Press releasePRNewswire
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
- NewsRishabh Mishra
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)
- NewsAvi Kapoor
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.